ZBTB11 and breast cancer: To assess whether the ZBTB11/DDX1 signalling axis affects sensitivity to cisplatin in BC cells, we used dose–response curves to analyse the half maximal inhibitory concentration (IC50) values for cisplatin in ZBTB11 knockdown BC cells with or without DDX1 rescue (Figure 7A).